tbuckley/cabot-search huggingface dataset:
Abstract 23: Trends in Kawasaki Disease Incidence - 2004-2014
Authors: Sara K Sexson Tejtel, Andrea A Ramirez, Amy Liou, Thomas Seery, Debra Canter, Marietta DeGuzman, Carolyn Altman
Journal: Circulation (2015)

Background: Kawasaki disease is the leading cause of acquired heart disease in children in the US. While it remains a rare disease, the purpose of this study is to evaluate the incidence of KD Methods: To evaluate our hypothesis we used the Pediatric Health Information Systems (PHIS), 2004-2013, including all discharges at 44 of the largest freestanding children’s hospitals in the US. Results: Between 2004-2013, there were 16,417 hospitalizations for KD, 10,388 (61%) were male. The race of patients admitted with KD showed 5276 (31%) Caucasian, 2370 (14%) African American, 1586 (9.3%) Other, and 941 (5.5%) Asian. The average length of stay 3.9 days. The number of patients with KD increased annually for the past decade, Figure 1. The largest proportion of the increase was from those children between 1 and 5 years of age, Figure 2. Most children were only hospitalized once (14,231, 84%) however some children required subsequent hospitalization (1,291,8%). Conclusions: There has been a steady increase in the number of admissions per year for Kawasaki disease predominately for those patients ages 1-5 years.
Maternal Obesity and Cardiac Development in the Offspring
Authors: Maria Angela Guzzardi, Tiziana Liistro, Luna Gargani, Lamia Ait Ali, Gennaro D’Angelo, Silvia Rocchiccioli, Federica La Rosa, Alessandra Kemeny, Elena Sanguinetti, Nadia Ucciferri, Mariarosaria De Simone, Antonietta Bartoli, Pierluigi Festa, Piero A. Salvadori, Silvia Burchielli, Rosa Sicari, Patricia Iozzo
Journal: JACC. Cardiovascular imaging (2017)
Primer brote de Escherichia coli O157 productor de verotoxina en Dinamarca
Authors: C Jensen, S Ethelberg, A Gervelmeyer, E M Nielsen, K Ep Olsen, K Mølbak
Journal: Eurosurveillance (2006)

El articulo siguiente describe el primer brote de Escherichia coli O157 productor de verotoxina ocurrido en la comunidad en Dinamarca. Entre septiembre de 2003 y marzo de 2004, se identificaron veinticinco pacientes (18 ninos y 7 adultos) que presentaban una infeccion por VTEC O157:H- confirmada por cultivo y tenian el mismo perfil de ADN por electroforesis en campo pulsado. La cepa epidemica poseia los genes de virulencia eae, vtx1 y vtx2c. Excepto por un paciente, todos tenian diarrea, pero ninguno el sindrome hemolitico uremico. El brote se limitaba a Copenhague y las areas vecinas. Un estudio de casos y controles apareados incluyendo 11 casos y 55 controles revelo asociacion entre la infeccion por VTEC O157:H- y el consumo de alimentos de una cadena de supermercados en Copenhague y vecindad : odds ratio apareada (OR) : 8,7, intervalo de confianza (IC) 95% :1,1-7,1. Despues de excluir del estudio tres casos asumidos como secundarios, solo el consumo de una leche biologica procedente de una pequena lecheria estaba asociado con la enfermedad : OR 8,7 (IC 95% 1,6-48). 
Las investigaciones ambientales y microbiologicas en la lecheria sospechosa no pudieron confirmar la presencia de la cepa epidemica, pero el brote se detuvo tras cerrar y limpiar completamente la lecheria.
Abstract 16504: Multipotent Compact Bone-Derived Stem Cells Support the Injured Heart through Transdifferentiation into Five Distinct Phenotypes
Authors: Jason M Duran, Thomas E Sharp, Timothy Starosta, Yumi Chiba, Remus M Berretta, John Gaughan, Hajime Kubo, Steven R Houser
Journal: Circulation (2012)

Introduction: Clinical trials have demonstrated moderate functional benefits of bone marrow-derived stem cells given after myocardial infarction (MI). Some animal studies have suggested that the me...
Abstract 21149: Long-Term Clinical Outcomes of Patients With Critical Limb Ischemia Underwent Percutaneous Transluminal Angioplasty and Routine Coronary Angiography
Authors: Seung-Woon Rha, Byoung Geol Choi, Ae-Young Her, Yong Hoon Kim, Se Yeon Choi, Jae Kyeong Byun, Yoonjee Park, Ahmed Mashaly, Won Young Jang, WooHyeun Kim, Jah Yeon Choi, Eun Jin Park, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Circulation (2017)

Background: Critical limb ischemia (CLI) and coronary artery disease (CAD) are associated with a high risk of mortality and cardiovascular events. Also, CAD is well-known for its higher prevalence in CLI patients (pts). We evaluated long-term clinical outcomes of the strategy of routine coronary angiography and subsequent coronary revascularization, if clinically indicated, in patients with CLI who underwent percutaneous transluminal angioplasty (PTA). Methods: A total 674 consecutive CLI patients underwent PTA and coronary angiography. Coronary artery disease (CAD) was defined as angiographic stenosis ≥70 %. Patients were divided into two groups according to the presence of CAD (CAD group: 413 pts, Non-CAD group: 261 pts). To adjust for any potential confounders that could cause bias, propensity score matching (PSM) analysis was performed. Clinical outcomes were assessed in a follow-up of 5 years by Kaplan-Meier curved analysis. Results: After PSM analysis, two matched groups (160 pairs, n=320 pts) were generated and their baseline characteristics were balanced. During the 5-year clinical follow-up, there were no differences between the two group regarding mortality, myocardial infarction, strokes, peripheral revascularization, and target extremity surgery except that the coronary revascularization was higher in the CAD group than the non-CAD group [Table]. Conclusion: A strategy of routine coronary angiography and coronary revascularization may be a reasonable treatment option for patients who have high risk for severe CAD at least for 5 years. A randomized trial is needed to determine if this is the preferred strategy for CLI patients.
Dynamics of the pneumonic plague epidemic in Madagascar, August to October 2017
Authors: Shinya Tsuzuki, Hyojung Lee, Fuminari Miura, Yat Hin Chan, Sung-mok Jung, Andrei R Akhmetzhanov, Hiroshi Nishiura
Journal: Eurosurveillance (2017)

Transmission potential and severity of pneumonic plague in Madagascar were assessed. Accounting for reporting delay, the reproduction number was estimated at 1.73. The case fatality risk was estimated as 5.5%. Expected numbers of exported cases from Madagascar were estimated across the world and all estimates were below 1 person from August to October, 2017.
Twice the Power in New MRI
Authors: Rebecca Voelker
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Plan de preparación y respuesta frente a una pandemia gripal en el ámbito comunitario
Authors: F Karcher, H Buchow
Journal: Eurosurveillance (2002)

Antecedentes En noviembre de 2001, la Comision Europea invito a especialistas de toda Europa a expresar su opinion sobre las distintas formas en que se puede mejorar la preparacion para una pandemia gripal que afecte a toda la Comunidad Europea. La conferencia conto con una nutrida participacion de asistentes y en ella se identificaron las principales medidas que las autoridades sanitarias deben emprender en colaboracion con los responsables de la toma de decisiones y el sector farmaceutico (1).
Are the risks of treatment to cure a child with severe sickle cell disease too high?
Authors: Mariane de Montalembert, Valentine Brousse, Subarna Chakravorty, Antonio Pagliuca, John Porter, Paul Telfer, Ajay Vora, David C Rees
Journal: BMJ (2017)

Haematopoietic stem cell transplantation from alternative donors is curative for children with sickle cell disease, but risk of death is high. <b>David Rees and colleagues</b> call for greater caution in its use
Parametric optimization of electric field strength for cancer electrochemotherapy on a chip-based model
Authors: Deyao Zhao, Mengxi Wu, Dong Huang, Zicai Liang, Zewen Wei, Zhihong Li
Journal: Theranostics (2017)

Electrochemotherapy (ECT), as one of the very few available treatments for cutaneous and subcutaneous tumors when surgery and radiotherapy are no longer available, requires applying a proper electric field to the tumor to realize electroporation-mediated cytotoxic drug delivery. It is impossible to exhaust all possible electrical parameters on patients to realize the optimal tradeoff between tumor suppression and adverse effects. To address this issue, this study provides a feasible solution by developing a four-leaf micro-electrode chip (F-MEC) in which the electric field was specially designed by linear distribution to cover all possible electric field strengths for ECT. Methods: We developed a F-MEC that provides a linearly varied electric field and a capacity for in situ observation of cell status. By culturing tumor cells on the F-MEC surface and in situ monitoring the cell responses to ECT drugs, the optimal electric field strength for any given cell type could be rapidly and accurately calculated in a few, or even only one, simple assay. Results: Using this chip, we monitored MCF-7 and A315 cell responses to ECT and determined the optimum ECT voltage. More importantly, we successfully verified that the in vitro determined voltage coincided with the optimal value for in vivo ECT in mice. Conclusion: In this proof-of-concept study, the in vivo tumor suppression assays proved that the optimal parameters acquired from in vitro F-MEC assay could be used for in vivo ECT.
Hair Repigmentation With Anti–PD-1 and Anti–PD-L1 Immunotherapy: A Novel Hypothesis
Authors: Guillaume Manson, Aurélien Marabelle, Roch Houot
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Human stem cell–derived astrocytes replicate human prions in a <i>PRNP</i> genotype–dependent manner
Authors: Zuzana Krejciova, James Alibhai, Chen Zhao, Robert Krencik, Nina M. Rzechorzek, Erik M. Ullian, Jean Manson, James W. Ironside, Mark W. Head, Siddharthan Chandran
Journal: The Journal of Experimental Medicine (2017)

Prions are infectious agents that cause neurodegenerative diseases such as Creutzfeldt–Jakob disease (CJD). The absence of a human cell culture model that replicates human prions has hampered prion disease research for decades. In this paper, we show that astrocytes derived from human induced pluripotent stem cells (iPSCs) support the replication of prions from brain samples of CJD patients. For experimental exposure of astrocytes to variant CJD (vCJD), the kinetics of prion replication occur in a prion protein codon 129 genotype–dependent manner, reflecting the genotype-dependent susceptibility to clinical vCJD found in patients. Furthermore, iPSC-derived astrocytes can replicate prions associated with the major sporadic CJD strains found in human patients. Lastly, we demonstrate the subpassage of prions from infected to naive astrocyte cultures, indicating the generation of prion infectivity in vitro. Our study addresses a long-standing gap in the repertoire of human prion disease research, providing a new in vitro system for accelerated mechanistic studies and drug discovery.
Back to blame: the Bawa-Garba case and the patient safety agenda
Authors: Deborah Cohen
Journal: BMJ (2017)

The case of Hadiza Bawa-Garba has left the UK medical profession rattled.Though there has been an outpouring of sympathy for the trainee paediatrician being pursued by the General Medical Council (GMC), 1 there is also an increasing sense that the case will leave the patient safety agenda in tatters by closing down any discussion of medical errors for fear of litigation.Bawa-Garba's fate will be decided in the High Court on 7 December when the GMC attempts to overturn a decision by the Medical Practitioners Tribunal Service to keep her on the medical register.She was convicted of gross negligence manslaughter in 2015 after the death of 6 year old Jack Adcock from sepsis at Leicester Royal Infirmary.
Outcomes of Positive Airway Pressure for Sleep Apnea
Authors: Shahrokh Javaheri, Francisco Campos-Rodriguez
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk of AMD has decreased over the past few generations, study finds
Authors: Susan Mayor
Journal: BMJ (2017)

The risk of age related macular degeneration (AMD) has decreased by more than 60% in each subsequent generation of people born throughout the twentieth century, a large US study has reported.1

“This dramatic decline in the incidence suggests that environmental or behavioral factors are important risk factors in the etiology of AMD,” the researchers, led by Karen Cruickshanks from the University of Wisconsin-Madison, Madison, US, said. “These results show that the epidemic of AMD …
Erratum: Corrigendum: Genome-wide DNA-methylation landscape defines specialization of regulatory T cells in tissues
Authors: Michael Delacher, Charles D Imbusch, Dieter Weichenhan, Achim Breiling, Agnes Hotz-Wagenblatt, Ulrike Träger, Ann-Cathrin Hofer, Danny Kägebein, Qi Wang, Felix Frauhammer, Jan-Philipp Mallm, Katharina Bauer, Carl Herrmann, Philipp A Lang, Benedikt Brors, Christoph Plass, Markus Feuerer
Journal: Nature Immunology (2017)
Preliminary results of a randomized controlled trial of early integration of specialist palliative care within a tertiary cancer center in the Czech Republic.
Authors: Ondrej Slama, Lukas Pochop, Lucie Svetlakova, Ondrej Bilek, Jiri Sedo, Renata Horova, Regina Demlova, Rostislav Vyzula
Journal: Journal of Clinical Oncology (2017)

113 Background: Clinical trials in the U.S. and Canada have shown the benefit for patients and the health care system of early integration of palliative care into oncological practice. Nevertheless the practical realisation and the timing of this integration may be controversial. The optimal model of specialist palliative care (SPC) involvement may depend on the quality of standard cancer care in the given country. Methods: We present preliminary results of a randomised controlled trial of early integration of SPC conducted in the largest tertiary cancer center in Czech Republic. The trial compares standard oncology care with integrated SPC to standard oncology care alone in patients with advanced solid tumors treated with palliative antineoplastic therapy. The design of the study is inspired by the study of early PC for patients with advanced NSCLC byTemel et al. (2010). The SPC intervention consists of consultations with palliative care team every 6 weeks. Outcomes assessed at baseline and at 3 and 6 months after enrollment are quality of life (EORTC-QoL-Q30), anxiety and depression (HADS) and structure and cost of end of life care. Results: 100 patients have been randomisd between September 2015 and January 2017 (integrated PC 51 pts, conotrole 49pts). There were differences at 3 and 6 months in QoL (66% vs. 55%, p &gt; 0,05; 63% vs. 49% p &gt; 0,05), prevalence of anxiety (37% vs. 43%, p &gt; 0,05; 32% vs. 54%, p &gt; 0,05) and depression (19% vs. 29% p = 0,02; 20% vs. 27% p &gt; 0,05) in intergated and control arm respectively. The mean time from the last chemotherapy to death was 66 days vs.52 days (p = 0,04) and the enrollment rate to hospice programme was 63% vs. 43% (p = 0,02) at the end of life in favour of integrated palliative care. Conclusions: There seem to be a trend for better results in patient reported outcomes and reasonable resource utilisation in favour of integrated care model in the context of advanced cancer care in Czech Republic. But differences between study arms did not reach statistical significance in patient reported outcomes, probably due to small number of patients. We hope to enrol enough patients within next 6 months to overcome this limitation.
P3.02b-034 Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients
Authors: Elisabetta Macerola, Rossella Bruno, Irene Prediletto, Elisa Sensi, Antonio Chella, Lorenza Landi, Greta Alì, Gabriella Fontanini
Journal: Journal of Thoracic Oncology (2017)
Margaret McCartney: Are physician associates just “doctors on the cheap”?
Authors: Margaret McCartney
Journal: BMJ (2017)

Jeremy Hunt tweeted on 18 September, “PAs [physician associates] used to be looked down on as ‘drs on the cheap’ but now widely welcomed as reducing clinician stress & burnout.”1 Is he right?

In 2015 the NHS sought to bring 200 physician associates from the US into English primary care and hospital specialties, through the National Physician Associate Expansion Programme.2 The aim was to train new physician associates (PAs) in the UK to work with, and then replace, the US sourced associates. Around 600 PAs now work in the UK, to rise to 3200 in the next three years. The training is a two year postgraduate course, and Hunt has mandated 1000 new posts in primary care.3

The Royal College of Physicians (RCP) has set up a Faculty …
Macitentan in daily clinical practice: A single centre, 1-year experience
Authors: S. Cadenas-Menéndez, P. Álvarez-Vega, J. Martín-Moreiras, M. Barreiro-Pérez, M.Á. Gómez-Sánchez, P.L. Sánchez-Fernández
Journal: Pulmonology (2017)

The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events. Our aim was to describe a single centre's experience of the utilization of macitentan in patients with PAH in clinical practice settings. Thirteen patients with different aetiologies and previous PAH treatments were studied. After 12 months of macitentan treatment, 11 patients improved their functional class (FC), all patients improved their 6-minute walk distance (6MWD) test, and 10 patients lowered their NT-proBNP plasma levels. Additionally, cardiac imaging parameters were also improved. No cases resulted in hospitalization, septostomy, transplant or death.
Genomic profiling of early-stage lung cancer for patterns of recurrence.
Authors: Costanzo A DiPerna, Leah Fine
Journal: Journal of Clinical Oncology (2017)

e23126 Background: Currently there is no evidence to support molecular profiling for early stage resected lung cancer patients. However, up to 50% of patients experience recurrence following resection. This is a first-of-a-kind study utilizing comprehensive genomic profiling technology to characterize genomic patterns for risk of recurrence in early stage lung cancer patients within the community hospital setting who have undergone lung surgery. Methods: A total of 60 Stage I-II lung cancer patients, all having undergone pulmonary resection, were evaluated with molecular profiling of their primary lung cancer tissue using Foundation Medicine’s FoundationOne Ò test. Patient age in years ranged from 39-86, and all patients were confirmed Stage I or II based on final pathologic analysis. Samples were taken from three community hospitals that are part of the Addario Lung Cancer Foundation Centers of Excellence program. Patients whose tumors were resected between the years of 2009-2017 were included in this combined retrospective and prospective study. Results: More than 300 genes were evaluated using FoundationOne Ò and patients were segmented to establish similarities and differences. Analysis of segments include gender, recurrence, smoking status among others. Gene patterns across segments are beginning to reveal possible predictive profiles. Final analysis will be completed shortly. Conclusions: Genomic profiling could help predict lung cancer recurrence for early stage lung cancer patients. Similarities amongst patients with recurrences imply that early genomic profiling of lung cancer patients could help predict those patients who would benefit from adjuvant therapies including conventional chemotherapy. Genomic profiling for early stage lung cancer should be studied further and in greater detail to help predict those patients who would benefit from potentially early adjuvant therapies.